First treatment recommended for rare progressive lung conditions in children and adolescents

View source ↗

Summary

The EMA's CHMP issued a positive opinion to extend the indication of nintedanib (Ofev) to treat rare progressive lung conditions in children and adolescents age…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Fibrosing Interstitial Lung Disease in Pediatric Patients

Drugs mentioned

• OFEV (Nintedanib)

Snippet

Positive opinion for extension of indication from age of six